If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi ® (glucagon) nasal powder
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Baqsimi™ (glucagon) nasal powder immunogenic?
There is a potential for immunogenicity with Baqsimi (glucagon) nasal powder as with all therapeutic peptides.
As with all therapeutic peptides, there is the potential for immunogenicity with Baqsimi.1
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody, including neutralizing antibody, positivity in an assay may be influenced by several factors including
- assay methodology
- sample handling
- timing of sample collection
- concomitant medications, and
- underlying disease.1
For these reasons, comparison of the incidence of antibodies to Baqsimi with the incidences of antibodies to other products may be misleading.1
In 3 clinical trials, 3/124 (2%) of participants treated with Baqsimi had treatment-emergent antidrug antibodies as detected by an affinity capture elution ligand-binding immunogenicity assay. No neutralizing antibodies were detected.1
Enclosed Prescribing Information
1Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Date of Last Review: January 06, 2022